August 29, 2012 (Munich, Germany) — A new prespecified analysis of the ARISTOTLE study has shown that the new oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was better than ...
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control ...
Bristol-Myers Squibb Company has announced that the company is voluntarily recalling one lot of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the US to wholesalers ...
Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of ELIQUIS for ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize ...
Please provide your email address to receive an email when new articles are posted on . In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke and systemic embolism vs.
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS ®. In this ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- ...
Researchers have found in a new study that among patients with subclinical atrial fibrillation (SCAF), apixaban caused more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results